Carisma Therapeutics, Inc.

NasdaqGM:CARM Rapporto sulle azioni

Cap. di mercato: US$35.4m

Carisma Therapeutics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Steve Kelly

Amministratore delegato

US$3.5m

Compenso totale

Percentuale dello stipendio del CEO13.2%
Mandato del CEO1.7yrs
Proprietà del CEOn/a
Durata media del management1.5yrs
Durata media del Consiglio di amministrazione1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Kelly rispetto agli utili di Carisma Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$461k

-US$87m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$80m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$666kUS$440k

-US$61m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$1mUS$416k

-US$41m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 3.50M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 650.80K ).

Compensazione vs guadagni: La retribuzione di Steve è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Steve Kelly (59 yo)

1.7yrs

Mandato

US$3,504,425

Compensazione

Mr. Steven Kelly, also known as Steve, is President, Chief Executive Officer and Director of Carisma Therapeutics, Inc. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Steven Kelly
President1.7yrsUS$3.50mNessun dato
Michael Klichinsky
Co-Founder & Chief Scientific Officer1.7yrsUS$1.60m1.16%
$ 410.6k
Richard Morris
CFO, Chief Compliance Officer1.7yrsUS$1.66m0%
$ 0
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Eric Siegel
General Counsel & Corporate Secretary1.4yrsNessun datoNessun dato
Terry Shields
Senior Vice President of Human Resources1.4yrsNessun datoNessun dato
Tom Wilton
Chief Business Officer4.8yrsNessun datoNessun dato
Eugene Kennedy
Chief Medical Officerless than a yearNessun datoNessun dato
Kenneth Locke
Senior Vice President of Technical Operationsless than a yearNessun datoNessun dato

1.5yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di CARM non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Steven Kelly
President1.7yrsUS$3.50mNessun dato
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Sanford Zweifach
Independent Chairman of the Board1.7yrsUS$271.55k0.00099%
$ 350.4
Hyam Levitsky
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Carl June
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Nina Bhardwaj
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
Briggs W. Morrison
Independent Director1.7yrsUS$220.20k0.029%
$ 10.3k
Marella Thorell
Directorless than a yearNessun datoNessun dato
John Hohneker
Independent Directorless than a yearNessun dato0%
$ 0
Lisa Coussens
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Prasad Adusumilli
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
Lin Guey
Member of Scientific Advisory Board1.8yrsNessun datoNessun dato

1.7yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CARM non è considerato esperto (durata media del mandato 1.7 anni), il che suggerisce un nuovo consiglio.